| CARVIEW |
Select Language
HTTP/2 301
date: Mon, 29 Dec 2025 08:35:05 GMT
content-type: text/html
content-length: 166
location: https://www.quiverbioscience.com/
server: cloudflare
cf-ray: 9b57f63ccfd44fd7-BOM
cf-cache-status: BYPASS
cache-control: private
strict-transport-security: max-age=31536000
vary: Accept-Encoding
set-cookie: _cfuvid=UABRIJpgl0S0HKxn1ua4zSDNRVpxnZ8RiuVieOjI7as-1766997305136-0.0.1.1-604800000; path=/; domain=.www.qstatebio.com; HttpOnly; Secure; SameSite=None
alt-svc: h3=":443"; ma=86400
HTTP/2 200
date: Mon, 29 Dec 2025 08:35:05 GMT
content-type: text/html
server: cloudflare
cf-ray: 9b57f6465a10ff9e-BOM
cf-cache-status: HIT
age: 62384
content-encoding: gzip
last-modified: Sun, 28 Dec 2025 15:15:20 GMT
strict-transport-security: max-age=31536000
surrogate-control: max-age=432000
surrogate-key: www.quiverbioscience.com 68014af91ea811b9d9fabf67 pageId:68014af91ea811b9d9fac02e 680fed57901a9d635d8d0125 680283be6c7a3b3f328d1d01 680299ce3a05cab51b4db9a8 68029c55e281afce216dbee2
x-lambda-id: 13855f67-1dae-4ef4-a30b-3e1647ec2802
vary: accept-encoding
set-cookie: _cfuvid=13SisJFojPnyciE08ZF1MNVcbS8wq63Y9me.v_0j.vA-1766997305666-0.0.1.1-604800000; path=/; domain=.www.quiverbioscience.com; HttpOnly; Secure; SameSite=None
alt-svc: h3=":443"; ma=86400
Quiver Bioscience - Home
Innovation
Innovation
Decoding neurons to unlock breakthrough cns therapeutics
Our Mission
Quiver Bioscience was built to create transformational medicines for patients living with disorders of the brain. Utilizing our human disease models, novel AI, and the best-in-world platform, we stand as the premier partner in the journey from target discovery to the clinic.
About Quiver
Innovation
across axes
Our approach integrates cutting-edge scalable biology, state-of-the-art technology and engineering, and learning and surrogate models to identify novel therapeutic targets and the best candidate molecules to deliver new and meaningful therapeutics to patients.
03
insights
AI models mine our high-dimensional data for key disease phenotypes and higher in-vivo-potential candidates.
01
Models
Patient-derived stem-cell models enhance translatability by capturing disease phenotypes.
02
signals
High-throughput optogenetic screening collects high dimensional data across 100s of cells in parallel.
Innovation
across axes
Our approach integrates cutting-edge scalable biology, state-of-the-art technology and engineering, and learning and surrogate models to identify novel therapeutic targets and the best candidate molecules to deliver new and meaningful therapeutics to patients.
01
Models
Patient-derived stem-cell models enhance translatability by capturing disease phenotypes.
02
signals
High-throughput optogenetic screening collects high dimensional data across 100s of cells in parallel.
03
insights
AI models mine our high-dimensional data for key disease phenotypes and higher in-vivo-potential candidates.
Therapuetic pipeline
Disorder/Target
Discovery
Pre-clinical
Clinical
Cell Models
Cell Phenotypes
Human Model POC
Screening
Optimization
Mouse ICV Tolerability
In Vivo Efficacy
Rat IT Tolerability
NHP Tolerability (Dev Cand.)
IND Enabling
Phase 1
Chronic Pain Disorders
Nav1.8 (Small Molecule)
Nav1.7 (ASO)
Nav1.8 (ASO)
Dual Nav1.7 / 1.8 (ASO)
Nav1.7 (Small Molecule)
Seizure and Neurodevelopment Disorders
Dup15q Syndrome - UBE3A (ASO)
DEE13 - SCN8A (ASO)
DEE4 - STXBP1 (ASO)
SYNGAP (ASO)
Tuberous Sclerosis Complex - TSC2 (Small Molecule)
Fragile X Syndrome – (ASO)
We welcome partnership opportunities with other organizations seeking to develop novel therapeutics for serious diseases or with parties interested in leveraging our unique capabilities.
Press
View All
October 7, 2025
Align Summit: Cambridge based Quiver Bioscience is developing ASOs for CNS conditions, including programs in the red hot Nav1.7/1.8 pain space
Read Article
July 1, 2025
Quiver Bioscience secures non-dilutive funding to enhance CNS genetic medicine drug discovery platform capabilities and advance powerful AI/ML-based in vitro / in silico predictor of CNS drug safety
Read Article
June 16, 2025
Quiver Bioscience Appoints Graham Dempsey, PhD as Chief Executive Officer to Lead Scaling of AI-Driven CNS Platform and Advance Lead Program into the Clinic
Read Article